Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.48 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4202733 | 0.98 | L3MBTL1 (0.47) | L3MBTL1MBTD1SFRP1SMN1; SMN2LMNA | |
| SCHEMBL4200851 | 0.90 | SIGMAR1 (0.45) | L3MBTL1MBTD1SMN1; SMN2LMNASIGMAR1 | |
| SCHEMBL4207698 | 0.80 | L3MBTL1 (0.46) | L3MBTL1MBTD1HTR7KMT2A | |
| SCHEMBL4195788 | 0.77 | HDAC2 (0.36) | SIGMAR1HTR7 | |
| SCHEMBL4194739 | 0.76 | USP2 (0.47) | L3MBTL1SMN1; SMN2KMT2A | |
| SCHEMBL12930425 | 0.75 | L3MBTL1 (0.54) | L3MBTL1MBTD1SFRP1SMN1; SMN2LMNA | |
| SCHEMBL4354178 | 0.75 | SMYD3 (0.41) | L3MBTL1MBTD1SMN1; SMN2 | |
| SCHEMBL4202177 | 0.73 | HRH3 (0.42) | SMN1; SMN2HTR7 | |
| SCHEMBL21610873 | 0.72 | L3MBTL1 (0.55) | L3MBTL1MBTD1SFRP1SMN1; SMN2LMNA | |
| SCHEMBL7258458 | 0.72 | L3MBTL1 (0.51) | L3MBTL1MBTD1SFRP1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275567-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| EP-2032559-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007138268-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275567-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | CCNI, MKI67, CDK2 | L3MBTL1 3228/4885MBTD1 2471/4885SFRP1 3765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.